Cardiovascular safety of psilocybin in psychiatric practice: a narrative review.

The largest and most consistent group differences occur about 60-90 min after dosing and generally resolve within 4-6 h; heart-rate effects are smaller and less consistent.

Risk interpretation changes with cardiovascular comorbidity, interacting medications, repeated exposure, and non-standardized mushroom products, whose active-alkaloid content can vary by more than an order of magnitude.

Mean QTc effects at standard exposure are small.